Skip to main content

Equibles does not estimate personal net worth.

Get an email with a short summary when CareDx, Inc. publishes a filing, an earnings call transcript or a press release.

Get CDNA alerts

About Keith Kennedy

Keith Kennedy is recorded as COO and CFO at CareDx, Inc. (CDNA). The newest filing on record that lists Keith Kennedy as CFO at CareDx, Inc. (CDNA) is dated April 27, 2026. The newest filing on record that lists Keith Kennedy as COO at CareDx, Inc. (CDNA) is dated April 28, 2025. Keith Kennedy was last confirmed as CFO at Veracyte, Inc. (VCYT) in a filing dated April 26, 2022. Earlier roles on record: CFO at Veracyte, Inc. (VCYT) until May 15, 2021. CareDx, Inc. reported in an 8-K filed September 12, 2024 that Keith Kennedy was appointed Chief Operating Officer. CareDx, Inc. reported in an 8-K filed September 12, 2024 that Keith Kennedy was appointed Chief Operating Officer, effective September 12, 2024. The proxy statement of CareDx, Inc. reports total compensation of $3,219,231 for Keith Kennedy in fiscal 2025, including a base salary of $587,606. Disclosed compensation is on record for 7 fiscal years. Keith Kennedy has spoken on 10 earnings calls and 1 other investor event across 2 companies, most recently for CareDx, Inc. on July 30, 2026. Those appearances were for CareDx, Inc. (CDNA) and Veracyte, Inc. (VCYT). CareDx, Inc. is classified in the Diagnostics & Research industry within the Healthcare sector. Other companies whose calls Keith Kennedy spoke on are classified in the Healthcare sector. Other leadership on record at CareDx, Inc. includes Alexander L. Johnson (CEO), John W. Hanna (CEO and Board Member), Michael D. Goldberg (Chairman and Board Member) and 7 others.

“CareDx Appoints Keith Kennedy Chief Operating Officer and Jessica Meng Chief Commercial Officer”
CareDx, Inc. Form 8-K, filed September 12, 2024 · Read the filing
“The Board of Directors of CareDx, Inc. (the "Company") has appointed Keith Kennedy, as the Company's Chief Operating Officer, effective September 12, 2024 (the "Effective Date").”
CareDx, Inc. Form 8-K, filed September 12, 2024 · Read the filing

Keith Kennedy on recent calls

“I'm planning to cover our second quarter 2026 financial results and our updated 2026 guidance. Turning to the financial highlights section of our earnings presentation for the second quarter 2026 and our year-over-year results.”
CFO, CareDx Q2’26 Earnings Call ·
“We were really excited about the first quarter, you know, printing almost a 40% growth year over year.”
CFO, Jefferies 2026 Global Healthcare Conference ·
“I plan to cover our first quarter 2026 financial results and our updated 2026 guidance. You may access our earnings presentation at caredx.com by clicking through to our investor page.”
COO, CareDx, Inc. Q1 FY2026 Earnings Call ·
“On the patient and digital solutions, we're assuming we're going to grow the product, patient, and digital solutions collectively in a range of 8% to 12% next year.”
COO, CareDx, Inc. Q4 FY2025 Earnings Call ·
“We have about 150 active discussions going on with hospitals and transplant centers across the country right now, and we anticipate going live at about 40 centers in '26.”
COO, CareDx, Inc. Q3 FY2025 Earnings Call ·

Affiliation history

Company network

Leadership on record at CareDx, Inc.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2025 CareDx, Inc. (CDNA) $587,606 $3,219,231
2024 CareDx, Inc. (CDNA) $148,173 $4,512,215
2021 Veracyte, Inc. (VCYT) $178,875 $2,654,814
2020 Veracyte, Inc. (VCYT) $450,000 $2,025,917
2019 Veracyte, Inc. (VCYT) $432,000 $2,773,676
2018 Veracyte, Inc. (VCYT) $400,000 $1,466,109
2017 Veracyte, Inc. (VCYT) $400,000 $792,685

Recent activity